Latest Breaking News On - Linda mellby - Page 1 : comparemela.com
Immunovia reports positive results of the blinded clinical validation of IMMray PanCan-d blood test in USA
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Immunovia reports improved test performance of IMMrayTM PanCan-d in detecting early stage pancreatic cancer in high risk symptomatic patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Immunovia publishes link to Webinar No. 3 on IMMray PanCan-d: Verification Study and Clinical Use
LUND, Sweden, Dec. 14, 2020 /PRNewswire/ Immunovia AB (publ) ( Immunovia ) today published the link to the company s third webinar in a series on IMMray PanCan-d, Immunovia s test for early detection of pancreatic cancer. The webinar will cover the IMMray PanCan-d verification study results and its clinical use, including feedback from experts in pancreatic cancer and pancreatic diseases.
Event Details:
Date and Time: December 17, 2020 at 15:00 CET
Moderator for the webinar: CEO Patrik Dahlen
Presenters: Thomas King, MD, PhD; Linda Mellby, PhD, VP R&D; and Laura Chirica, CCO, PhD, Immunovia
About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique disease biomarker signature .
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2.
(1)
LUND, Sweden, Dec. 11, 2020 /PRNewswire/ Immunovia AB (publ) ( Immunovia ), a near-commercial stage diagnostics company developing ground-breaking antibody-based multiplex microarray technology platform called IMMray for the early detection of cancer, today announced that the company will be hosting the third webinar in the series on IMMray PanCan-d, Immunovia s test for early detection of pancreatic cancer. This third webinar will cover IMMray
PanCan-d verification study results and its clinical use including feedback from experts in pancreatic cancer and pancreatic diseases.
Event Details: Webinar No. 3: Immunovia s IMMray PanCan-d Webinar Series Verification Study and Clinical Use
Date and Time: December 17, 2020 at 15:00 CET
Moderator for the Webinar is CEO Patrik Dahlen
vimarsana © 2020. All Rights Reserved.